Document is current
Any future updates will be listed below
-
Authors
Liu, Tina Y. https://orcid.org/0000-0003-1297-7102
Liu, Jun-Jie
Aditham, Abhishek J.
Nogales, Eva https://orcid.org/0000-0001-9816-3681
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P01GM051487, F32GM122334)
Life Sciences Research Foundation
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 29 January 2019
Accepted: 28 May 2019
First Online: 5 July 2019
Competing Interests
: J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Scribe Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Synthego, Metagenomi, Mammoth Biosciences, and Inari. J.A.D is a member of the board of directors at Johnson & Johnson, and has sponsored research projects supported by Pfizer, Inc. and Biogen. The remaining authors declare no competing interests.
